Autologous Wnt-activated ADSC Therapy
Alzheimer's Disease
Key Facts
About Regeneration Biomedical
Regeneration Biomedical is a private, pre-revenue biotech advancing a first-in-class, autologous stem cell therapy platform targeting major neurodegenerative diseases. Its core innovation is the intracranial delivery of Wnt-activated adipose-derived stem cells, aiming to modulate inflammation and promote regeneration within the brain. The company is led by a team with decades of medical and research experience and is currently recruiting for a Phase 1 trial in Alzheimer's disease, with a broad pipeline intended for ALS, Multiple Sclerosis, Parkinson's, stroke, and TBI. Its success hinges on demonstrating safety and efficacy in its ongoing clinical work and navigating the complex regulatory pathway for a novel biologic intervention.
View full company profileAbout Regeneration Biomedical
Regeneration Biomedical is a private, pre-revenue biotech advancing a first-in-class, autologous stem cell therapy platform targeting major neurodegenerative diseases. Its core innovation is the intracranial delivery of Wnt-activated adipose-derived stem cells, aiming to modulate inflammation and promote regeneration within the brain. The company is led by a team with decades of medical and research experience and is currently recruiting for a Phase 1 trial in Alzheimer's disease, with a broad pipeline intended for ALS, Multiple Sclerosis, Parkinson's, stroke, and TBI. Its success hinges on demonstrating safety and efficacy in its ongoing clinical work and navigating the complex regulatory pathway for a novel biologic intervention.
View full company profileAbout Regeneration Biomedical
Regeneration Biomedical is a private, pre-revenue biotech advancing a first-in-class, autologous stem cell therapy platform targeting major neurodegenerative diseases. Its core innovation is the intracranial delivery of Wnt-activated adipose-derived stem cells, aiming to modulate inflammation and promote regeneration within the brain. The company is led by a team with decades of medical and research experience and is currently recruiting for a Phase 1 trial in Alzheimer's disease, with a broad pipeline intended for ALS, Multiple Sclerosis, Parkinson's, stroke, and TBI. Its success hinges on demonstrating safety and efficacy in its ongoing clinical work and navigating the complex regulatory pathway for a novel biologic intervention.
View full company profileAbout Regeneration Biomedical
Regeneration Biomedical is a private, pre-revenue biotech advancing a first-in-class, autologous stem cell therapy platform targeting major neurodegenerative diseases. Its core innovation is the intracranial delivery of Wnt-activated adipose-derived stem cells, aiming to modulate inflammation and promote regeneration within the brain. The company is led by a team with decades of medical and research experience and is currently recruiting for a Phase 1 trial in Alzheimer's disease, with a broad pipeline intended for ALS, Multiple Sclerosis, Parkinson's, stroke, and TBI. Its success hinges on demonstrating safety and efficacy in its ongoing clinical work and navigating the complex regulatory pathway for a novel biologic intervention.
View full company profileAbout Regeneration Biomedical
Regeneration Biomedical is a private, pre-revenue biotech advancing a first-in-class, autologous stem cell therapy platform targeting major neurodegenerative diseases. Its core innovation is the intracranial delivery of Wnt-activated adipose-derived stem cells, aiming to modulate inflammation and promote regeneration within the brain. The company is led by a team with decades of medical and research experience and is currently recruiting for a Phase 1 trial in Alzheimer's disease, with a broad pipeline intended for ALS, Multiple Sclerosis, Parkinson's, stroke, and TBI. Its success hinges on demonstrating safety and efficacy in its ongoing clinical work and navigating the complex regulatory pathway for a novel biologic intervention.
View full company profileAbout Regeneration Biomedical
Regeneration Biomedical is a private, pre-revenue biotech advancing a first-in-class, autologous stem cell therapy platform targeting major neurodegenerative diseases. Its core innovation is the intracranial delivery of Wnt-activated adipose-derived stem cells, aiming to modulate inflammation and promote regeneration within the brain. The company is led by a team with decades of medical and research experience and is currently recruiting for a Phase 1 trial in Alzheimer's disease, with a broad pipeline intended for ALS, Multiple Sclerosis, Parkinson's, stroke, and TBI. Its success hinges on demonstrating safety and efficacy in its ongoing clinical work and navigating the complex regulatory pathway for a novel biologic intervention.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |